XNAS
ATTO
, Last price
USD
Name
Attovia Therapeutics Inc
Chart & performance
P/E
—
P/S
—
EPS
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
Net income
CFO
Dividend
Nov 09, 20170.3384 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Valuation
No data to show